<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Evaluation of hypertension in children and adolescents</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Evaluation of hypertension in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Evaluation of hypertension in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jun 02, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>It has become clear that hypertension (HTN) begins in childhood and adolescence, and that it contributes to the early development of cardiovascular disease (CVD).</p><p>The evaluation of children with HTN will be reviewed here. The epidemiology, etiology, diagnosis, and treatment of childhood HTN are discussed separately. (See  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents"</a>.)</p><p>In addition, the evaluation for hypertensive emergency is presented elsewhere. (See  <a class="medical medical_review" href="/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION</span><span class="headingEndMark"> — </span>The following terms are used throughout this topic:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypertension (HTN)</strong> – In pediatric patients, hypertension (HTN) is defined as follows (see  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children &lt;13 years old, the definition is based upon blood pressure (BP) percentiles for sex, age, and height, as summarized in the tables  (<a class="graphic graphic_table graphicRef114574" href="/d/graphic/114574.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 3</a>) [<a href="#rid1">1</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In adolescents ≥13 years old, the definition is aligned with adult guidelines  (<a class="graphic graphic_table graphicRef114574" href="/d/graphic/114574.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary versus secondary HTN </strong>– Childhood HTN is categorized as primary (essential) or secondary depending upon whether an underlying cause can be identified  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>).</p><p></p><p class="headingAnchor" id="H1951123521"><span class="h1">IMPORTANCE</span><span class="headingEndMark"> — </span>There is good evidence that identifying children with HTN and successfully treating their primary HTN has an important impact on long-term cardiovascular outcomes. Pediatric data include clinical studies that demonstrate cardiovascular structural and functional changes in children with HTN, and autopsy studies that have shown an association of blood pressure (BP) with atherosclerotic changes in the aorta and coronary arteries of children and young adults. Children with primary HTN are likely to continue to have HTN as adults, and clinical trials in adults have shown that antihypertensive therapy reduces cardiovascular morbidity and mortality. In patients with secondary HTN, clinical outcomes vary depending on the underlying etiology and whether the underlying cause is amenable to treatment. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Rationale for intervention'</a> and  <a class="medical medical_review" href="/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents", section on 'Tracking'</a>.)</p><p>Thus, one of the most important components of the successful management of childhood HTN is distinguishing between primary and secondary HTN, and identifying the cause of secondary hypertension, if present. </p><p class="headingAnchor" id="H6"><span class="h1">INITIAL EVALUATION</span></p><p class="headingAnchor" id="H1822702223"><span class="h2">Goals</span><span class="headingEndMark"> — </span>The goals of the evaluation are to:</p><p class="bulletIndent1"><span class="glyph">●</span>Distinguish between primary and secondary HTN  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify any treatable conditions that may be causing or contributing to HTN  (<a class="graphic graphic_table graphicRef73738" href="/d/graphic/73738.html" rel="external">table 5</a>). (See  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Etiology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify other comorbid conditions or risk factors for early cardiovascular disease (CVD), including obesity, dyslipidemia, and diabetes mellitus  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify patients for whom antihypertensive drug therapy is warranted. The presence of another CVD risk factor or disease associated with a high risk of CVD impacts the timing and choice of intervention for high BP. Indications for pharmacologic therapy are discussed separately. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Who should be treated'</a>.) </p><p></p><p>Most children and adolescents with HTN, particularly those who are likely to have secondary HTN, should be referred to a pediatric nephrologist or other clinician experienced in childhood HTN.</p><p class="headingAnchor" id="H7"><span class="h2">History and physical examination</span></p><p class="headingAnchor" id="H3391369556"><span class="h3">Assess for symptoms attributable to hypertension</span><span class="headingEndMark"> — </span>Symptoms consistent with hypertensive emergencies include headache, seizures, changes in mental status, vomiting, focal neurologic complaints, visual disturbances, and cardiovascular (CV) complaints indicative of heart failure (such as chest pain, palpitations, cough, or shortness of breath). Children with hypertensive emergency require pharmacologic therapy without delay and hospitalization for evaluation and ongoing care. (See  <a class="medical medical_review" href="/d/html/6438.html" rel="external">"Approach to hypertensive emergencies and urgencies in children"</a> and  <a class="medical medical_review" href="/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Secondary versus primary hypertension</span><span class="headingEndMark"> — </span>An important focus of the history and physical examination is to differentiate secondary from primary HTN by looking for signs and symptoms that are associated with specific underlying etiologies for HTN  (<a class="graphic graphic_table graphicRef76420" href="/d/graphic/76420.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef76824" href="/d/graphic/76824.html" rel="external">table 8</a>).</p><p>Secondary HTN should be suspected in children with <strong>any</strong> of the following findings  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Prepubertal, particularly younger than six years of age.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A thin child with a negative family history for HTN. (See  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Nonmodifiable risk factors'</a> and  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Modifiable risk factors'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An acute rise in blood pressure (BP) above a previously stable baseline.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Specific ambulatory BP patterns, such as sustained diastolic HTN, nocturnal HTN, and/or blunted nocturnal dipping. (See  <a class="medical medical_review" href="/d/html/6124.html" rel="external">"Ambulatory blood pressure monitoring in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Past history of the following suggests renal disease as an underlying etiology:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Urinary tract infection, especially pyelonephritis</p><p class="bulletIndent2"><span class="glyph">•</span>Congenital kidney or urologic anomalies </p><p class="bulletIndent2"><span class="glyph">•</span>Perinatal history of neonatal umbilical arterial catheterization, oligohydramnios, or perinatal anoxia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of snoring, daytime sleepiness (in adolescents), or hyperactivity (in younger children) are associated with obstructive sleep apnea. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children", section on 'Clinical manifestations'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Family history of chronic or congenital renal disease (such as polycystic kidney disease), or other genetic conditions that are associated with HTN, such as neurofibromatosis or tuberous sclerosis. (See  <a class="medical medical_review" href="/d/html/2939.html" rel="external">"Neurofibromatosis type 1 (NF1): Pathogenesis, clinical features, and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/1684.html" rel="external">"Renal manifestations of tuberous sclerosis complex"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>History of drugs known to increase BP including glucocorticoids, central nervous system stimulants, decongestants with <a class="drug drug_pediatric" data-topicid="12747" href="/d/drug information/12747.html" rel="external">pseudoephedrine</a>, or oral contraceptives. Recreational drugs, including anabolic steroids and stimulants (eg, cocaine and amphetamine).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Physical finding(s) suggestive of systemic disease or a specific secondary etiology of HTN include  (<a class="graphic graphic_table graphicRef76824" href="/d/graphic/76824.html" rel="external">table 8</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cutaneous findings associated with tuberous sclerosis (ash leaf spots or adenoma sebaceum) or neurofibromatosis (café-au-lait spots and neurofibromas).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ambiguous genitalia may be suggestive of congenital adrenal hyperplasia with excess endogenous secretion of androgens and mineralocorticoids. Children with mineralocorticoid excess may develop hypokalemia. (See  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Edema may be indicative of kidney disease or heart failure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Clinical findings of arthritis or rash may be suggestive of glomerulonephritis due to systemic disorders, such as immunoglobulin A vasculitis (IgAV; Henoch-Schönlein purpura [HSP]) or systemic lupus erythematosus (SLE). Abdominal pain may also be present in patients with IgAV (HSP). (See  <a class="medical medical_review" href="/d/html/6406.html" rel="external">"IgA vasculitis (Henoch-Schönlein purpura): Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/6420.html" rel="external">"Childhood-onset systemic lupus erythematosus (SLE): Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The presence of an abdominal bruit raises the possibility of renovascular disease, but its absence does not exclude the diagnosis.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Coarctation of the aorta is suggested by findings of hypertension in the upper extremities, low or unobtainable blood pressure in the lower extremities, and diminished or delayed femoral pulses. (See  <a class="medical medical_review" href="/d/html/5760.html" rel="external">"Clinical manifestations and diagnosis of coarctation of the aorta"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Symptoms suggestive of catecholamine excess in addition to elevated BP include headache, sweating, and tachycardia. Possible etiologies include pheochromocytoma, neuroblastoma, or use of sympathomimetic drugs (eg, phenylpropanolamine [an over-the-counter decongestant], cocaine, amphetamines, phencyclidine, <a class="drug drug_pediatric" data-topicid="13272" href="/d/drug information/13272.html" rel="external">epinephrine</a>, <a class="drug drug_pediatric" data-topicid="12701" href="/d/drug information/12701.html" rel="external">phenylephrine</a>, and <a class="drug drug_pediatric" data-topicid="12826" href="/d/drug information/12826.html" rel="external">terbutaline</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Findings suggestive of hyperthyroidism include tachycardia, proptosis, or enlarged thyroid or goiter. Of note, HTN, particularly diastolic HTN, is associated with hypothyroidism. Clinical symptoms of hypothyroidism in children include weight gain, exercise intolerance, constipation, fatigue, and cold intolerance.</p><p></p><p class="headingAnchor" id="H9"><span class="h3">Assess for other CVD risk factors</span><span class="headingEndMark"> — </span>The history and physical examination should assess for risk factors that contribute to high BP and early CVD [<a href="#rid1">1</a>]  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 6</a>).</p><p class="bulletIndent1"><span class="glyph">●</span>Assess for traditional CVD risk factors (see  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Traditional ASCVD risk factors'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Family history – Review the family history to assess whether there is a history of premature CVD in other family members.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Obesity – Calculate the calculating body mass index (BMI) to identify overweight/obese children (for girls: (<a class="calc calc_professional" href="/d/html/13415.html" rel="external">calculator 1</a>)  (<a class="graphic graphic_figure graphicRef90747" href="/d/graphic/90747.html" rel="external">figure 1</a>); for boys: (<a class="calc calc_professional" href="/d/html/13412.html" rel="external">calculator 2</a>)  (<a class="graphic graphic_figure graphicRef91083" href="/d/graphic/91083.html" rel="external">figure 2</a>)). (See  <a class="medical medical_review" href="/d/html/5874.html" rel="external">"Definition, epidemiology, and etiology of obesity in children and adolescents"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Smoking or smoke exposure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Type 1 or 2 diabetes mellitus. (See  <a class="medical medical_review" href="/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Cardiovascular disease'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Dyslipidemia. (See  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review the medical history for other conditions associated with increased CVD risk (eg, chronic kidney disease [CKD], organ transplantation, cardiac disease, childhood cancer, Kawasaki disease, autoimmune disease, familial hypercholesterolemia, HIV infection, and adolescent depressive and bipolar disorders). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Other conditions'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review the history to determine if the child has a known sleep disorder or symptoms concerning for obstructive sleep apnea (loud snoring, daytime sleepiness, or attention problems) [<a href="#rid1">1-5</a>]. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Identify children with a sedentary lifestyle in whom increased physical activity may improve BP. Increased physical activity is also an important part of managing children who are overweight or obese (BMI &gt;85<sup>th</sup> percentile). (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Exercise'</a> and  <a class="medical medical_review" href="/d/html/15848.html" rel="external">"Prevention and management of childhood obesity in the primary care setting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Review the dietary history to identify dietary contributors to HTN (excess salt intake) and CVD risk (consumption of high-fat foods) and identify interventions that may decrease BP. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Diet'</a> and  <a class="medical medical_review" href="/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Heart-healthy diet'</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h3">Physical findings of end-organ damage</span><span class="headingEndMark"> — </span>The physical examination should assess for the following findings that suggest end-organ damage due to HTN:</p><p class="bulletIndent1"><span class="glyph">●</span>Retinal vascular changes due to HTN  (<a class="graphic graphic_diagnosticimage graphicRef104437" href="/d/graphic/104437.html" rel="external">image 1</a>) (see  <a class="medical medical_review" href="/d/html/3859.html" rel="external">"Ocular effects of hypertension"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Cardiac heave or laterally displaced point of maximal impulse (PMI), which may indicate left ventricular hypertrophy (LVH)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">Laboratory evaluation</span><span class="headingEndMark"> — </span>Initial laboratory evaluation in all children with persistent HTN is directed at determining the etiology of HTN and identifying other CVD risk factors, especially in obese children [<a href="#rid1">1</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Testing to perform in all children and adolescents with HTN</strong> – We concur with the following initial evaluation for all children with HTN recommended by the 2017 American Academy of Pediatrics (AAP) guidelines for high BP [<a href="#rid1">1</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum blood urea nitrogen (BUN), creatinine, and electrolytes </p><p class="bulletIndent2"><span class="glyph">•</span>Urinalysis</p><p class="bulletIndent2"><span class="glyph">•</span>Lipid profile (see  <a class="medical medical_review" href="/d/html/16972.html" rel="external">"Dyslipidemia in children and adolescents: Definition, screening, and diagnosis", section on 'Choice of screening test'</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Additional testing for children who are obese</strong> (see  <a class="medical medical_review" href="/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity", section on 'Routine blood tests'</a>):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemoglobin A1c (screen for diabetes mellitus).</p><p class="bulletIndent2"><span class="glyph">•</span>Serum alanine transaminase (screen for fatty liver).</p><p class="bulletIndent2"><span class="glyph">•</span>In our practice, we also will obtain a fasting serum glucose if the urinalysis detects glycosuria.</p><p></p><p>These tests permit quick assessment of kidney function, potassium homeostasis, and acid-base status. In addition, they screen for common comorbid conditions associated with increased CVD risk (eg, diabetes mellitus and dyslipidemia). </p><p>The <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fjournals.lww.com%2Fjhypertension%2Fpages%2Farticleviewer.aspx%3Fyear%3D2016%26issue%3D10000%26article%3D00002%26type%3Dabstract&amp;token=UtHiD5B5t0wyVc1pQopiMMeaqTqPm2HDoV8gomXzmADto4A6mUgj2aNCURoNW5FKwPjpzV7P0cAYY4SNts5WHSvcAlsHGqCuCkkb6T8GIrXGAj7crs0C%2FJOCQppNJYZjLz8Q3SBfDwQntSqlIMVpHA%3D%3D&amp;TOPIC_ID=6088" target="_blank">2016 European Hypertension Society guidelines</a> for the management of high blood pressure in children and adolescents includes a more extensive initial evaluation [<a href="#rid6">6</a>].</p><p class="headingAnchor" id="H357931708"><span class="h2">Kidney ultrasound</span><span class="headingEndMark"> — </span>In our tertiary center, we obtain a kidney ultrasound as part of the initial evaluation for all patients referred for HTN evaluation. Other centers perform ultrasonography more selectively. The 2017 AAP high BP guidelines recommend a kidney ultrasound initially for children presenting with HTN at age &lt;6 years and those with laboratory findings concerning for kidney disease (eg, abnormal kidney function tests or urinalysis) [<a href="#rid1">1</a>]. Ultrasonography is useful to determine the presence of both kidneys, presence of any congenital anomaly, or disparate kidney size, which may suggest scarring. </p><p class="headingAnchor" id="H3182605263"><span class="h2">Detection of end-organ damage</span></p><p class="headingAnchor" id="H282773969"><span class="h3">Echocardiography</span><span class="headingEndMark"> — </span>Left ventricular hypertrophy (LVH) is the most prominent manifestation of end-organ damage from HTN. LVH is associated with adverse cardiovascular disease (CVD) outcomes, and a significant number of children and adolescents with HTN have LVH [<a href="#rid7">7-12</a>].</p><p>Echocardiography is the recommended modality to detect LVH due to pediatric HTN. The 2017 American Association of Pediatrics (AAP) high blood pressure (BP) guidelines recommends echocardiography to assess for target-organ cardiac damage be performed at the time when pharmacologic therapy is being considered [<a href="#rid1">1</a>]. For children ≥8 to 18 years, LVH is defined as LV mass &gt;51 g/m<sup>2.7</sup>. For children &lt;8 years, LVH is defined as LV mass &gt;115 g/body surface area (BSA) for males, and LV mass &gt;95 g/BSA for females. </p><p>The recommended interval for subsequent echocardiographic assessment is based on the results of the initial study [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For children without evidence of LV target organ damage, echocardiography is performed in 12 months for patients whose BP is not well controlled despite intervention with pharmacologic and nonpharmacologic therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For children with evidence of LV target organ damage, echocardiography is performed at six months to monitor for improvement or progression of damage. The results of the study and BP control are used to determine the scheduling of future studies.</p><p></p><p>Electrocardiography should not be performed to assess for end-organ cardiac damage, as the study is not sensitive enough to reliably identify pediatric patients with LVH [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4230003065"><span class="h3">Assessments that are not recommended</span><span class="headingEndMark"> — </span>Studies have shown that elevated BP in childhood is associated with adverse changes in preclinical measures of atherosclerotic CVD (eg, carotid intima-media thickness, pulse wave velocity, flow-mediated dilation); however, these changes have not been directly correlated with CVD events in adulthood [<a href="#rid1">1</a>]. In addition, there are insufficient pediatric data to define threshold values for these measurements to guide clinical decision-making in children with HTN. As a result, use of these tools is generally limited to research settings and they are not recommended in routine clinical practice [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H12"><span class="h1">FURTHER EVALUATION</span><span class="headingEndMark"> — </span>If the history, physical examination, and initial laboratory evaluation suggest a secondary cause of HTN  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef73738" href="/d/graphic/73738.html" rel="external">table 5</a>), further evaluation to determine the underlying etiology may be warranted. </p><p class="headingAnchor" id="H13"><span class="h2">Primary hypertension</span><span class="headingEndMark"> — </span>Hypertensive children who fit the primary HTN profile need no further laboratory evaluation beyond the initial testing cited above  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>) [<a href="#rid1">1,6</a>].</p><p>Data are insufficient to determine whether measurements of serum uric acid and microalbuminuria are useful in the evaluation and management of pediatric primary HTN [<a href="#rid1">1</a>]. As a result, routine assessment of uric acid and microalbuminuria is not recommended in the care of children with elevated BP.</p><p class="headingAnchor" id="H14"><span class="h2">Secondary hypertension</span><span class="headingEndMark"> — </span>Further evaluation of patients with findings suggestive of secondary HTN is directed towards identifying the underlying cause. (See <a class="local">'Secondary versus primary hypertension'</a> above and  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Secondary hypertension'</a>.)</p><p>The following diagnostic studies may be performed in hypertensive children with a high degree of suspicion that an underlying disorder is present [<a href="#rid13">13</a>].</p><p class="headingAnchor" id="H16"><span class="h3">Plasma renin and aldosterone activity</span><span class="headingEndMark"> — </span>Evaluation of plasma renin and aldosterone activity (PRA) may be useful in patients in the following uncommon conditions:</p><p class="bulletIndent1"><span class="glyph">●</span>Excess mineralocorticoids (eg, aldosterone) secretion – Patients with mineralocorticoid excess usually present with hypokalemia and metabolic alkalosis and their PRA is low and often unmeasurable. (See  <a class="medical medical_review" href="/d/html/140.html" rel="external">"Pathophysiology and clinical features of primary aldosteronism"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Congenital adrenal hyperplasia is a common cause of excess mineralocorticoid secretion in children. Affected patients may present as a neonate with ambiguous genitalia due to the excess secretion of androgens. (See  <a class="medical medical_review" href="/d/html/5813.html" rel="external">"Causes of primary adrenal insufficiency in children", section on 'Congenital adrenal hyperplasia'</a> and  <a class="medical medical_review" href="/d/html/5803.html" rel="external">"Evaluation of the infant with atypical genital appearance (difference of sex development)"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Aldosterone-secreting tumors, which are rare in children. Patients with primary hyperaldosteronism have low renin and high serum aldosterone with an aldosterone to renin ratio &gt;30 (aldosterone in nanograms/dL and PRA in nanograms per mL/hour).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Primary hypersecretion of aldosterone may result from familial hyperaldosteronism, a group of rare genetic disorders, including glucocorticoid-remediable hyperaldosteronism (GRA). GRA should be considered in a hypertensive child with a family history of early HTN (before age 21 years) and evidence of metabolic alkalosis even in the absence of hypokalemia. (See  <a class="medical medical_review" href="/d/html/122.html" rel="external">"Familial hyperaldosteronism"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Suppressed mineralocorticoids – Rare genetic disorders with low levels of aldosterone and renin, despite presenting with symptoms suggestive of mineralocorticoid excess, include Liddle syndrome, pseudohypoaldosteronism type 2 (also referred to as Gordon syndrome) and syndrome of apparent mineralocorticoid excess. (See  <a class="medical medical_review" href="/d/html/2371.html" rel="external">"Genetic disorders of the collecting tubule sodium channel: Liddle syndrome and pseudohypoaldosteronism type 1", section on 'Liddle syndrome'</a> and  <a class="medical medical_review" href="/d/html/2306.html" rel="external">"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'</a> and  <a class="medical medical_review" href="/d/html/2346.html" rel="external">"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renin-secreting tumor – Renin-secreting tumors are rare both in children and adults. Patients generally present with severe HTN, hypokalemia, metabolic alkalosis, and markedly elevated renin levels [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renovascular disease – The plasma renin activity may be elevated in children with renovascular HTN, but, as is true in adults, it is a relatively insensitive test. Approximately 15 percent of children with arteriographically evident renal artery stenosis have normal plasma renin activity [<a href="#rid15">15,16</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary free cortisone to cortisol ratio – Patients with apparent mineralocorticoid excess syndrome have decreased 24-hour urinary free cortisone to cortisol ratio.</p><p></p><p class="headingAnchor" id="H17"><span class="h3">Plasma and urine catecholamines</span><span class="headingEndMark"> — </span>Patients with HTN due to disorders with catecholamine excess such as pheochromocytoma and neuroblastoma will have elevated levels of both plasma and urine catecholamines and metabolites. In addition to HTN, affected patients may present with headache, sweating, and tachycardia. In patients with symptoms of catecholamine excess and elevated plasma and urine catecholamines, further evaluation is required. (See  <a class="medical medical_review" href="/d/html/5850.html" rel="external">"Pheochromocytoma and paraganglioma in children"</a> and  <a class="medical medical_review" href="/d/html/5187.html" rel="external">"Clinical presentation, diagnosis, and staging evaluation of neuroblastoma"</a>.)</p><p class="headingAnchor" id="H1611242723"><span class="h3">Kidney imaging</span><span class="headingEndMark"> — </span>As previously discussed, we obtain a kidney ultrasound as part of the initial evaluation for all patients referred for HTN evaluation at our tertiary center. Other centers perform ultrasonography more selectively. (See <a class="local">'Kidney ultrasound'</a> above.)</p><p>In patients with a strong suspicion for renal scarring based on history (eg, recurrent febrile urinary tract infections) or with a suggestive but indeterminant finding on kidney ultrasound, a 99mTc–<a class="drug drug_pediatric" data-topicid="12808" href="/d/drug information/12808.html" rel="external">dimercaptosuccinic acid</a> (DMSA) scan can be performed, since it is a more sensitive study to detect cortical loss and scarring [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H18"><span class="h3">Renovascular imaging</span><span class="headingEndMark"> — </span>In our practice, renovascular imaging is considered when infants and children have known predisposing factors or findings associated with renal artery stenosis such as prior umbilical artery catheter placements, family history or findings for neurofibromatosis, an abdominal bruit, or a significant size discrepancy on renal ultrasonography. In addition, we consider renovascular imaging in younger children with HTN, who are less likely to have primary HTN, and in patients with stage 2 HTN when no other cause has been identified. (See  <a class="medical medical_review" href="/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Kidney disease'</a>.)</p><p>Standard digital subtraction angiography (DSA), previously called renal angiography, is the current gold standard for evaluating renovascular disease in children [<a href="#rid18">18</a>]. Magnetic resonance angiography (MRA) and computed tomographic angiography (CTA) have also been used to screen for renovascular diseases [<a href="#rid19">19</a>], although they are not usually as reliable as DSA in detecting renovascular disease [<a href="#rid18">18</a>]. If renovascular evaluation is required, a radiological center with pediatric experience in these screening techniques should be chosen. The selection of the screening modality is dependent upon the expertise of the clinical staff and the availability of appropriate equipment and development of safe and useful protocols [<a href="#rid20">20</a>]. (See  <a class="medical medical_review" href="/d/html/3825.html" rel="external">"Establishing the diagnosis of renovascular hypertension"</a>.)</p><p>We do <strong>not</strong> recommend routine duplex Doppler ultrasonography for evaluation of renovascular hypertension in otherwise healthy children because of its low sensitivity/specificity for diagnosis of renal artery stenosis [<a href="#rid18">18</a>].</p><p>For children, these procedures are not universally available or routinely performed. Considerations that must be taken into account in the use of these modalities to screen for renovascular disease in children include:</p><p class="bulletIndent1"><span class="glyph">●</span>When performing MRA, the need for conscious sedation or general anesthesia for small children and infants.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The need to modify computed tomographic (CT) dosing to minimize unnecessary radiation exposures.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The poorer sensitivity of Doppler ultrasonography compared with other imaging modalities in detecting renal vascular hypertension, especially in patients who have segmental artery lesions [<a href="#rid21">21,22</a>]. As a result, Doppler ultrasound should not be used to diagnose renal artery stenosis.</p><p></p><p class="headingAnchor" id="H2030829092"><span class="h3">Sleep study evaluation</span><span class="headingEndMark"> — </span>Evaluation of obstructive sleep apnea (OSA), including polysomnography is considered for children with history of snoring, daytime sleepiness (in adolescents), or hyperactivity (in younger children), especially if they are obese. (See  <a class="medical medical_review" href="/d/html/6363.html" rel="external">"Evaluation of suspected obstructive sleep apnea in children", section on 'Evaluation'</a>.)</p><p class="headingAnchor" id="H2497524653"><span class="h3">Drug screening</span><span class="headingEndMark"> — </span>If HTN is suspected due to cocaine or amphetamine use, drug testing should be initiated. (See  <a class="medical medical_review" href="/d/html/303.html" rel="external">"Cocaine: Acute intoxication", section on 'Laboratory and radiographic evaluation'</a> and  <a class="medical medical_review" href="/d/html/311.html" rel="external">"Methamphetamine: Acute intoxication", section on 'Laboratory evaluation'</a>.)</p><p class="headingAnchor" id="H2489815365"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/109575.html" rel="external">"Society guideline links: Hypertension in children"</a>.)</p><p class="headingAnchor" id="H20"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15659.html" rel="external">"Patient education: High blood pressure in children (The Basics)"</a>)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/1190.html" rel="external">"Patient education: High blood pressure in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H21"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and importance</strong> – Hypertension (HTN) in childhood and adolescence contributes to premature cardiovascular disease (CVD). HTN is defined as follows (see <a class="local">'Definition'</a> above and <a class="local">'Importance'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children &lt;13 years old, HTN is defined based upon blood pressure (BP) percentiles for sex, age, and height, as summarized in the tables  (<a class="graphic graphic_table graphicRef114574" href="/d/graphic/114574.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef63856" href="/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/d/graphic/52646.html" rel="external">table 3</a>).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In adolescents ≥13 years old, the definition is aligned with adult guidelines  (<a class="graphic graphic_table graphicRef114574" href="/d/graphic/114574.html" rel="external">table 1</a>). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Goals of evaluation</strong> – The goals of the evaluation of a child or adolescent with HTN include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Determine whether the patient is more likely to have primary (essential) or secondary HTN  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>). Identify any treatable conditions that may be causing or contributing to HTN  (<a class="graphic graphic_table graphicRef73738" href="/d/graphic/73738.html" rel="external">table 5</a>). Children with likely secondary HTN need further evaluation and management by a specialist experienced in childhood HTN. (See <a class="local">'Secondary versus primary hypertension'</a> above and <a class="local">'Secondary hypertension'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identify other comorbid conditions or risk factors for early CVD (eg, obesity, dyslipidemia, diabetes mellitus)  (<a class="graphic graphic_table graphicRef109927" href="/d/graphic/109927.html" rel="external">table 6</a>). (See  <a class="medical medical_review" href="/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Identify children for whom antihypertensive drug therapy is appropriate. (See  <a class="medical medical_review" href="/d/html/6131.html" rel="external">"Nonemergent treatment of hypertension in children and adolescents", section on 'Who should be treated'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial evaluation</strong> – The initial evaluation includes the following steps which help establish whether the HTN is primary or secondary  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a>) (see <a class="local">'Initial evaluation'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History and physical examination  (<a class="graphic graphic_table graphicRef76420" href="/d/graphic/76420.html" rel="external">table 7</a> and <a class="graphic graphic_table graphicRef76824" href="/d/graphic/76824.html" rel="external">table 8</a>) (see <a class="local">'History and physical examination'</a> above)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory tests, including (see <a class="local">'Laboratory evaluation'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum BUN, creatinine, electrolytes</p><p class="bulletIndent3"><span class="glyph">-</span>Lipid profile </p><p class="bulletIndent3"><span class="glyph">-</span>Urinalysis</p><p class="bulletIndent3"><span class="glyph">-</span>For obese children, testing should also include hemoglobin A1c and alanine transaminase</p><p class="bulletIndent3"><span class="glyph">-</span>If drug abuse is suspected, testing should also include drug screening</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney ultrasound – We obtain a kidney ultrasound in all patients referred to our center for evaluation of HTN; other centers perform ultrasound selectively in patients presenting with HTN at a young age (&lt;6 years) or if there is laboratory evidence of kidney disease (abnormal kidney function tests or urinalysis). (See <a class="local">'Kidney ultrasound'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Echocardiography – If pharmacologic antihypertensive therapy is being considered, an echocardiogram should be obtained to assess for left ventricular hypertrophy (LVH), which is the most prominent manifestation of end-organ damage from HTN. (See <a class="local">'Echocardiography'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Further evaluation for underlying causes </strong>– If the history, physical examination, and initial laboratory evaluation suggest a secondary cause of HTN  (<a class="graphic graphic_table graphicRef101809" href="/d/graphic/101809.html" rel="external">table 4</a> and <a class="graphic graphic_table graphicRef73738" href="/d/graphic/73738.html" rel="external">table 5</a>), further evaluation to determine the underlying etiology may be warranted. Depending on the results of the initial evaluation, this may include renal imaging studies (eg, renal scans or arteriogram); measurement of plasma renin, aldosterone, and plasma and urine catecholamines; and/or sleep study. (See <a class="local">'Secondary hypertension'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Marcus CL, Greene MG, Carroll JL. Blood pressure in children with obstructive sleep apnea. Am J Respir Crit Care Med 1998; 157:1098.</a></li><li><a class="nounderline abstract_t">Enright PL, Goodwin JL, Sherrill DL, et al. Blood pressure elevation associated with sleep-related breathing disorder in a community sample of white and Hispanic children: the Tucson Children's Assessment of Sleep Apnea study. Arch Pediatr Adolesc Med 2003; 157:901.</a></li><li><a class="nounderline abstract_t">Li AM, Au CT, Ho C, et al. Blood pressure is elevated in children with primary snoring. J Pediatr 2009; 155:362.</a></li><li><a class="nounderline abstract_t">Horne RS, Yang JS, Walter LM, et al. Elevated blood pressure during sleep and wake in children with sleep-disordered breathing. Pediatrics 2011; 128:e85.</a></li><li><a class="nounderline abstract_t">Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887.</a></li><li><a class="nounderline abstract_t">Brady TM, Fivush B, Flynn JT, Parekh R. Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension. J Pediatr 2008; 152:73.</a></li><li><a class="nounderline abstract_t">Belsha CW, Wells TG, McNiece KL, et al. Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension. Am J Hypertens 1998; 11:410.</a></li><li><a class="nounderline abstract_t">Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003; 111:61.</a></li><li><a class="nounderline abstract_t">Hanevold C, Waller J, Daniels S, et al. The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association. Pediatrics 2004; 113:328.</a></li><li><a class="nounderline abstract_t">Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 1998; 97:1907.</a></li><li><a class="nounderline abstract_t">Schieken RM, Schwartz PF, Goble MM. Tracking of left ventricular mass in children: race and sex comparisons: the MCV Twin Study. Medical College of Virginia. Circulation 1998; 97:1901.</a></li><li><a class="nounderline abstract_t">Hansen ML, Gunn PW, Kaelber DC. Underdiagnosis of hypertension in children and adolescents. JAMA 2007; 298:874.</a></li><li><a class="nounderline abstract_t">Friedman K, Wallis T, Maloney KW, et al. An unusual cause of pediatric hypertension. J Pediatr 2007; 151:206.</a></li><li><a class="nounderline abstract_t">Dillon MJ, Ryness JM. Plasma renin activity and aldosterone concentration in children. Br Med J 1975; 4:316.</a></li><li><a class="nounderline abstract_t">Guzzetta PC, Potter BM, Ruley EJ, et al. Renovascular hypertension in children: current concepts in evaluation and treatment. J Pediatr Surg 1989; 24:1236.</a></li><li><a class="nounderline abstract_t">Ahmed M, Eggleston D, Kapur G, et al. Dimercaptosuccinic acid (DMSA) renal scan in the evaluation of hypertension in children. Pediatr Nephrol 2008; 23:435.</a></li><li><a class="nounderline abstract_t">Trautmann A, Roebuck DJ, McLaren CA, et al. Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension. Pediatr Nephrol 2017; 32:495.</a></li><li><a class="nounderline abstract_t">Orman G, Masand PM, Kukreja KU, et al. Diagnostic sensitivity and specificity of CT angiography for renal artery stenosis in children. Pediatr Radiol 2021; 51:419.</a></li><li><a class="nounderline abstract_t">Castelli PK, Dillman JR, Smith EA, et al. Imaging of renin-mediated hypertension in children. AJR Am J Roentgenol 2013; 200:W661.</a></li><li><a class="nounderline abstract_t">Chhadia S, Cohn RA, Vural G, Donaldson JS. Renal Doppler evaluation in the child with hypertension: a reasonable screening discriminator? Pediatr Radiol 2013; 43:1549.</a></li><li><a class="nounderline abstract_t">Castelli PK, Dillman JR, Kershaw DB, et al. Renal sonography with Doppler for detecting suspected pediatric renin-mediated hypertension - is it adequate? Pediatr Radiol 2014; 44:42.</a></li></ol></div><div id="topicVersionRevision">Topic 6088 Version 62.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9563725" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Blood pressure in children with obstructive sleep apnea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12963596" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Blood pressure elevation associated with sleep-related breathing disorder in a community sample of white and Hispanic children: the Tucson Children's Assessment of Sleep Apnea study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19540515" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Blood pressure is elevated in children with primary snoring.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21708802" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Elevated blood pressure during sleep and wake in children with sleep-disordered breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467768" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18154904" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ability of blood pressure to predict left ventricular hypertrophy in children with primary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9607378" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Influence of diurnal blood pressure variations on target organ abnormalities in adolescents with mild essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509555" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14754945" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The effects of obesity, gender, and ethnic group on left ventricular hypertrophy and geometry in hypertensive children: a collaborative study of the International Pediatric Hypertension Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609083" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609082" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Tracking of left ventricular mass in children: race and sex comparisons: the MCV Twin Study. Medical College of Virginia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17712071" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Underdiagnosis of hypertension in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17643780" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : An unusual cause of pediatric hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1192047" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Plasma renin activity and aldosterone concentration in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2593053" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Renovascular hypertension in children: current concepts in evaluation and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18026997" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dimercaptosuccinic acid (DMSA) renal scan in the evaluation of hypertension in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27747454" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Non-invasive imaging cannot replace formal angiography in the diagnosis of renovascular hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33151345" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Diagnostic sensitivity and specificity of CT angiography for renal artery stenosis in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23701100" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Imaging of renin-mediated hypertension in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23860636" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Renal Doppler evaluation in the child with hypertension: a reasonable screening discriminator?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037085" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Renal sonography with Doppler for detecting suspected pediatric renin-mediated hypertension - is it adequate?</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
